Pfizer Corporation

Agouron Pharmaceuticals, Inc.

Recurium IP Holdings, LLC

Suzhou Kintor Pharmaceuticals, Inc.

Zeno Royalties & Milestones, LLC

Pfizer Products Inc.

Chuangxing Guo

Liming Dong

Yufeng Hong

Haitao Li

Anle Yang

Kevin Duane Bunker

Mehmet Kahraman

Joseph Robert Pinchman

Joseph Timothy Marakovits

Junhu Zhang

Chad Daniel Hopkins

Indrawan James McAlpine

Deborah Helen Slee

Mary Catherine Johnson

Susan Elizabeth Kephart

Mark Charles Grier

Djamal Bouzida

Jingrong Jean Cui

Robert Steven Kania

Cynthia Louise Palmer

Peter Qinhua Huang

Judith Gail Deal

Jayashree Tikhe

Maria Angelica Linton

Mason Alan Pairish

Jesus Ernest Villafranca

Qinhua Huang

Youzhi Tong

Xinjun J Hou

Danlin Gu

Junhun Zhang

Darin Vanderpool

Jayashree Girish Tikhe

Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or behaviors mediated by an mTOR kinase and/or one or more PI3K enzyme, are provided. Such diseases and disorder include cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof

Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.

Bicyclic compounds

Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4. 

Pyrrolopyrazoles, potent kinase inhibitors

Pyrrolopyrazole, potent kinase inhibitors

Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4. 

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

The present invention is directed to compounds of Formula (I), and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

Pyrazole compounds as RAF inhibitors

The present invention concerns methods, pharmaceutical compounds, and compositions for stimulating neuroite outgrowth in nerve cells leading to nerve regeneration. These methods, compounds and compositions inhibit rotamase enzyme activity associated with binding proteins.

Compounds, compositions, and methods for stimulating neuronal growth and elongation

Growing community of inventors

San Diego, CA, United States of America

Chuangxing Guo